SCAI

This channel contains news about the Society for Cardiac Angiography and Interventions (SCAI), including coverage of its annual meeting and links to recently released practice guidelines. SCAI is a leading resource in interventional cardiology and cath lab techniques and technologies. 
 

One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021
Feature | Coronavirus (COVID-19) | By Dave Fornell, Editor

May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial ...

Home May 03, 2021
Home
News | Cath Lab

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
News | Congenital Heart

May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for ...

Home May 01, 2021
Home
Videos | Structural Heart

Ashwin Nathan M.D., a cardiology fellow at the Hospital of the University of Pennsylvania, presented a late-breaking ...

Home April 30, 2021
Home
The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 
Feature | Structural Heart | Dave Fornell, Editor

April 30, 2021 — New study results validate the effectiveness of the Medtronic Harmony transcatheter pulmonary valve ...

Home April 30, 2021
Home
The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).
Feature | Structural Heart

April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United ...

Home April 30, 2021
Home
News | Cath Lab

April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American ...

Home April 29, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
News | Radial Access | Dave Fornell, Editor

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

Home April 28, 2021
Home
Videos | Cardiogenic Shock

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

Home April 28, 2021
Home
News | Cath Lab

April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular ...

Home April 28, 2021
Home
News

April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the ...

Home April 20, 2021
Home
The Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System. It is first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT) to stop severe pulmonary valve regurgitation caused by congenital heart disease.
Feature | Structural Heart | By Dave Fornell, Editor

March 26, 2021 — Today, the U.S. Food and Drug Administration (FDA) cleared the Medtronic Harmony Transcatheter ...

Home March 26, 2021
Home
Subscribe Now